Cargando…

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Detalles Bibliográficos
Autores principales: Ottmann, Oliver, Saglio, Giuseppe, Apperley, Jane F., Arthur, Christopher, Bullorsky, Eduardo, Charbonnier, Aude, Dipersio, John F., Kantarjian, Hagop, Khoury, Hanna Jean, Kim, Dong-Wook, Healey, Diane, Strauss, Lewis, Cortes, Jorge E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127283/
https://www.ncbi.nlm.nih.gov/pubmed/30190469
http://dx.doi.org/10.1038/s41408-018-0122-3
_version_ 1783353443465822208
author Ottmann, Oliver
Saglio, Giuseppe
Apperley, Jane F.
Arthur, Christopher
Bullorsky, Eduardo
Charbonnier, Aude
Dipersio, John F.
Kantarjian, Hagop
Khoury, Hanna Jean
Kim, Dong-Wook
Healey, Diane
Strauss, Lewis
Cortes, Jorge E.
author_facet Ottmann, Oliver
Saglio, Giuseppe
Apperley, Jane F.
Arthur, Christopher
Bullorsky, Eduardo
Charbonnier, Aude
Dipersio, John F.
Kantarjian, Hagop
Khoury, Hanna Jean
Kim, Dong-Wook
Healey, Diane
Strauss, Lewis
Cortes, Jorge E.
author_sort Ottmann, Oliver
collection PubMed
description
format Online
Article
Text
id pubmed-6127283
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-61272832018-09-07 Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib Ottmann, Oliver Saglio, Giuseppe Apperley, Jane F. Arthur, Christopher Bullorsky, Eduardo Charbonnier, Aude Dipersio, John F. Kantarjian, Hagop Khoury, Hanna Jean Kim, Dong-Wook Healey, Diane Strauss, Lewis Cortes, Jorge E. Blood Cancer J Correspondence Nature Publishing Group UK 2018-09-03 /pmc/articles/PMC6127283/ /pubmed/30190469 http://dx.doi.org/10.1038/s41408-018-0122-3 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Correspondence
Ottmann, Oliver
Saglio, Giuseppe
Apperley, Jane F.
Arthur, Christopher
Bullorsky, Eduardo
Charbonnier, Aude
Dipersio, John F.
Kantarjian, Hagop
Khoury, Hanna Jean
Kim, Dong-Wook
Healey, Diane
Strauss, Lewis
Cortes, Jorge E.
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
title Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
title_full Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
title_fullStr Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
title_full_unstemmed Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
title_short Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
title_sort long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127283/
https://www.ncbi.nlm.nih.gov/pubmed/30190469
http://dx.doi.org/10.1038/s41408-018-0122-3
work_keys_str_mv AT ottmannoliver longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib
AT sagliogiuseppe longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib
AT apperleyjanef longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib
AT arthurchristopher longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib
AT bullorskyeduardo longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib
AT charbonnieraude longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib
AT dipersiojohnf longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib
AT kantarjianhagop longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib
AT khouryhannajean longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib
AT kimdongwook longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib
AT healeydiane longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib
AT strausslewis longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib
AT cortesjorgee longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib